DAKO HERCEPTEST
Agilent Technologies Singapore (International) Pte , Ltd. · Decision date Sep 25, 1998
What did the FDA approve?
The September 25, 1998 approval covers the DAKO HercepTest as a semi-quantitative immunohistochemical assay for detecting HER2 overexpression in routinely processed breast cancer tissues. The stated indication is as an aid in assessing patients for whom HERCEPTIN (trastuzumab) treatment is being considered.
The record does not describe a supplement, manufacturing change, or modification to an earlier PMA. No clinical trial data, performance metrics, or safety and effectiveness conclusions appear in the source statement. The device is classified under product code MVC as a HER-2/neu immunohistochemistry test system, with Agilent Technologies Singapore listed as the applicant.
FDA approval order statement
Approval for the DAKO Herceptest. This device is a semi-quantitative immunohistochemical assay to determine HER2 overexpression in breast cancer tissues routinely processed for histological evaluation. HercepTest is indicated as an aid in the assessment of patients for whom HERCEPTIN(R)(Transtuzumab) treatment is being considered.
- Regulatory pathway
- Original PMA
- Clinical specialty
- Pathology
- Decision date
- Sep 25, 1998
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P980018
- Regulatory pathway
- Premarket approval application
- Product code
- MVC
- Decision code
- APPR
- Decision date
- Sep 25, 1998
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: SYSTEM, TEST, HER-2/NEU, IHC.
- Product code
- MVC
- FDA device class
- 3
The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.
FDA decision timeline
P980018 received
Application receipt date recorded by FDA.
P980018 · FDA decision
APPR
P980018/S027 · Related supplement
HercepTest
Timeline entries are records held by MedtechLedger for P980018. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P980018
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
HercepTestP980018/S027 | Agilent Technologies Singapore (International) Pte , Ltd. | PMA supplement | Sep 21, 2026 | FDA |
Regulatory context
An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Agilent Technologies Singapore (International) Pte , Ltd.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- # 1 Yishun Ave. 7, Singapore, 768923
Sources and methodology
- Original FDA record: P980018
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records